The main purpose of this first-in-human study is to generate sufficient safety and immunogenicity data to enable the selection of an appropriate dose level for the initiation of a Phase 2/3 study.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, learn about Clinical
|Ages Eligible for Study||Min Age: 50 years - Max Age: N/A|
|Sexes Eligible for Study||All|
|Accepts Healthy Volunteers||Yes|